Drug profile · INN
maraviroc
CELSENTRI
maraviroc (CELSENTRI) is a c-c chemokine receptor type 5 antagonist. Associated with ViiV Healthcare Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — maraviroc
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
maraviroc (CELSENTRI) is a c-c chemokine receptor type 5 antagonist. Associated with ViiV Healthcare Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
C-C chemokine receptor type 5 antagonist
Primary target: C-C chemokine receptor type 5
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is maraviroc?
maraviroc (CELSENTRI) is a c-c chemokine receptor type 5 antagonist. Associated with ViiV Healthcare Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for maraviroc?
CELSENTRI is a marketed brand name for maraviroc. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of maraviroc?
maraviroc has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.